Clinical Trials
17
Active:7
Completed:7
Trial Phases
3 Phases
Phase 1:11
Phase 3:4
Phase 4:1
Drug Approvals
2
CANADA:1
Drug Approvals
PREHEVBRIO
CANADA
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (68.8%)Phase 3
4 (25.0%)Phase 4
1 (6.3%)PREHEVBRIO Pregnancy Outcomes Registry
Recruiting
- Conditions
- Vaccine Exposure During Pregnancy
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- VBI Vaccines Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06097312
- Locations
- 🇺🇸
ProPharma, Recruiting Nationwide, Overland Park, Kansas, United States
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
Phase 1
Withdrawn
- Conditions
- Coronavirus InfectionsCOVID-19
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- VBI Vaccines Inc.
- Registration Number
- NCT05614245
- Locations
- 🇨🇦
Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada
🇨🇦Red Maple Trials, Ottawa, Ontario, Canada
🇨🇦Ottawa Hospital, Ottawa, Ontario, Canada
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
Phase 1
Active, not recruiting
- Conditions
- COVID-19Coronavirus Infections
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- VBI Vaccines Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT05548439
- Locations
- 🇨🇦
Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada
🇨🇦Red Maple Trials, Ottawa, Ontario, Canada
🇨🇦Ottawa Hospital, Ottawa, Ontario, Canada
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
Phase 1
Completed
- Conditions
- Covid19
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- VBI Vaccines Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT04773665
- Locations
- 🇨🇦
Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada
🇨🇦Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦LMC Manna - Bayview CPU, Toronto, Ontario, Canada
A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults
Phase 3
Completed
- Conditions
- Hepatitis B
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- VBI Vaccines Inc.
- Target Recruit Count
- 402
- Registration Number
- NCT04531098
- Locations
- 🇻🇳
National Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam
- Prev
- 1
- 2
- 3
- Next
News
No news found